Prognostic value of the miRNA-27a and PPAR/RXRα signaling axis in patients with thyroid carcinoma

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
  MedlineGoogle Scholar
• 2. Fiore M, Oliveri Conti G, Caltabiano R et al. Role of emerging environmental risk factors in thyroid cancer: a brief review. Int. J. Environ. Res. Public Health 16(7), 1185 (2019).
  CASGoogle Scholar
• 3. Hińcza K, Kowalik A, Kowalska A. Current knowledge of germline genetic risk factors for the development of non-medullary thyroid cancer. Genes 10(7), 482 (2019).
  CASGoogle Scholar
• 4. Pishkari S, Paryan M, Hashemi M, Baldini E, Mohammadi-Yeganeh S. The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies. J. Endocrinol. Invest. 41(3), 269–283 (2018). • Highlights the functional role and aberrant expression of miRNAs in different types of thyroid carcinoma and the potential implication for future targeted therapy.
  Medline CASGoogle Scholar
• 5. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet 388(10061), 2783–2795 (2016).
  Medline CASGoogle Scholar
• 6. Nettore I, Colao A, Macchia P. Nutritional and environmental factors in thyroid carcinogenesis. Int. J. Environ. Res. Public Health 15(8), 1735 (2018).
  Google Scholar
• 7. Haugen BR, Alexander EK, Bible KC et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1), 1–133 (2016).
  MedlineGoogle Scholar
• 8. Grant CS. Recurrence of papillary thyroid cancer after optimized surgery. Gland. Surg. 4(1), 52–62 (2015).
  MedlineGoogle Scholar
• 9. Eszlinger M, Paschke R. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol. Cell Endocrinol. 322(1–2), 29–37 (2010).
  Medline CASGoogle Scholar
• 10. Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167–1214 (2009).
  MedlineGoogle Scholar
• 11. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104(6), 947–953 (1988).
  Medline CASGoogle Scholar
• 12. Prasad NB, Somervell H, Tufano RP et al. Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin. Cancer Res. 14(11), 3327–3337 (2008).
  Medline CASGoogle Scholar
• 13. Dai L, Wang Y, Chen L, Zheng J, Li J, Wu X. MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer. World J. Surg. Oncol. 15(1), 11 (2017).
  MedlineGoogle Scholar
• 14. Macfarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Curr. Genomics 11(7), 537–561 (2010).
  Medline CASGoogle Scholar
• 15. Toraih EA, Fawzy MS, Mohammed EA, Hussein MH, El-Labban MM. MicroRNA-196a2 biomarker and targetome network analysis in solid tumors. Mol. Diagn. Ther. 20(6), 559–577 (2016).
  Medline CASGoogle Scholar
• 16. Toraih EA, Ibrahiem AT, Fawzy MS, Hussein MH, Al-Qahtani SaM, Shaalan AaM. MicroRNA-34a: a key regulator in the hallmarks of renal cell carcinoma. Oxid. Med. Cell Longev. 2017, 3269379 (2017).
  MedlineGoogle Scholar
• 17. Toraih EA, Aly NM, Abdallah HY et al. MicroRNA-target cross-talks: key players in glioblastoma multiforme. Tumour Biol. 39(11), 1010428317726842 (2017).
  Google Scholar
• 18. Toraih EA, El-Wazir A, Abdallah HY, Tantawy MA, Fawzy MS. Deregulated microRNA signature following glioblastoma irradiation. Cancer Control 26(1), 1073274819847226 (2019).
  Google Scholar
• 19. Fawzy MS, Toraih EA, Ibrahiem A, Abdeldayem H, Mohamed AO, Abdel-Daim MM. Evaluation of miRNA-196a2 and apoptosis-related target genes: ANXA1, DFFA and PDCD4 expression in gastrointestinal cancer patients: a pilot study. PLoS ONE 12(11), e0187310 (2017).
  MedlineGoogle Scholar
• 20. Fawzy MS, Toraih EA, Ageeli EA, Al-Qahtanie SA, Hussein MH, Kandil E. Noncoding RNAs orchestrate cell growth, death and drug resistance in renal cell carcinoma. Epigenomics 12(3), 199–219 (2020).
  CASGoogle Scholar
• 21. Pallante P, Visone R, Ferracin M et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr. Relat. Cancer 13(2), 497–508 (2006).
  Medline CASGoogle Scholar
• 22. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J. Clin. Endocrinol. Metab. 93(5), 1600–1608 (2008). • One of the first to discuss that various histopathological types of thyroid tumors have distinct miRNA profiles that further differ within the same tumor type, reflecting specific oncogenic mutations.
  Medline CASGoogle Scholar
• 23. He H, Jazdzewski K, Li W et al. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl Acad. Sci. U S A 102(52), 19075–19080 (2005).
  Medline CASGoogle Scholar
• 24. Tetzlaff MT, Liu A, Xu X et al. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr. Pathol. 18(3), 163–173 (2007).
  Medline CASGoogle Scholar
• 25. Chen YT, Kitabayashi N, Zhou XK, Fahey TJ, Scognamiglio T 3rd. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod. Pathol. 21(9), 1139–1146 (2008).
  Medline CASGoogle Scholar
• 26. Lee JC, Zhao JT, Clifton-Bligh RJ et al. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer 119(24), 4358–4365 (2013).
  Medline CASGoogle Scholar
• 27. Li X, Xu M, Ding L, Tang J. MiR-27a: a novel biomarker and potential therapeutic target in tumors. J. Cancer 10(12), 2836–2848 (2019). •• Discusses the role of miR-27a in tumor biology and clinical significance in detail, offering novel insights into molecular targeting therapy for human cancers.
  Medline CASGoogle Scholar
• 28. Sun B, Li J, Shao D et al. Adipose tissue-secreted miR-27a promotes liver cancer by targeting FOXO1 in obese individuals. Onco. Targets Ther. 8, 735–744 (2015).
  Medline CASGoogle Scholar
• 29. Fletcher CE, Dart DA, Sita-Lumsden A, Cheng H, Rennie PS, Bevan CL. Androgen-regulated processing of the oncomir miR-27a, which targets prohibitin in prostate cancer. Hum. Mol. Genet. 21(14), 3112–3127 (2012).
  Medline CASGoogle Scholar
• 30. Colangelo T, Polcaro G, Ziccardi P, Pucci B, Muccillo L, Galgani M. Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer. Cell Death Dis. 7(2), e2120 (2016).
  Medline CASGoogle Scholar
• 31. Zhou S, Huang Q, Zheng S, Lin K, You J, Zhang X. MiR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis. Tumour Biol. 37(5), 6837–6845 (2016).
  Medline CASGoogle Scholar
• 32. Sun Y, Yang X, Liu M, Tang H. B4GALT3 up-regulation by miR-27a contributes to the oncogenic activity in human cervical cancer cells. Cancer Lett. 375(2), 284–292 (2016).
  Medline CASGoogle Scholar
• 33. Wang YL, Gong WG, Yuan QL. Effects of miR-27a upregulation on thyroid cancer cells migration, invasion, and angiogenesis. Genet. Mol. Res. 15(4), (2016).
  Google Scholar
• 34. Raman P, Koenig RJ. Pax-8-PPAR-gamma fusion protein in thyroid carcinoma. Nat. Rev. Endocrinol. 10(10), 616–623 (2014).
  Medline CASGoogle Scholar
• 35. Placzkowski KA, Reddi HV, Grebe SK, Eberhardt NL, Mciver B. The role of the PAX8/PPARgamma fusion oncogene in thyroid cancer. PPAR Res. 2008, 672829 (2008).
  MedlineGoogle Scholar
• 36. Marques AR, Espadinha C, Frias MJ et al. Underexpression of peroxisome proliferator-activated receptor (PPAR) gamma in PAX8/PPARgamma-negative thyroid tumours. Br. J. Cancer 91(4), 732–738 (2004).
  Medline CASGoogle Scholar
• 37. Espadinha C, Pinto AE, Leite V. Underexpression of PPARgamma is associated with aneuploidy and lower differentiation of thyroid tumours of follicular origin. Oncol. Rep. 22(4), 907–913 (2009).
  Medline CASGoogle Scholar
• 38. Wood WM, Sharma V, Bauerle KT et al. PPARgamma promotes growth and invasion of thyroid cancer cells. PPAR Res. 2011, 171765 (2011).
  MedlineGoogle Scholar
• 39. Hayashi N, Nakamori S, Hiraoka N et al. Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma. Int. J. Oncol. 24(1), 89–95 (2004).
  Medline CASGoogle Scholar
• 40. Klaunig JE, Babich MA, Baetcke KP et al. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 33(6), 655–780 (2003).
  Medline CASGoogle Scholar
• 41. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat. Rev. Cancer. 4(1), 61–70 (2004).
  Medline CASGoogle Scholar
• 42. Macejova D, Galbavy S, Podoba J, Bialesova L, Brtko J. MRNA expression pattern of retinoic acid and retinoid X nuclear receptor subtypes in human thyroid papillary carcinoma. Oncol. Rep. 30(5), 2371–2378 (2013).
  MedlineGoogle Scholar
• 43. Hoftijzer HC, Liu YY, Morreau H et al. Retinoic acid receptor and retinoid X receptor subtype expression for the differential diagnosis of thyroid neoplasms. Eur. J. Endocrinol. 160(4), 631–638 (2009).
  Medline CASGoogle Scholar
• 44. Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, Haugen BR. Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol. Cancer Ther. 3(8), 1011–1020 (2004).
  Medline CASGoogle Scholar
• 45. Casella C, Ministrini S, Galani A, Mastriale F, Cappelli C, Portolani N. The new TNM staging system for thyroid cancer and the risk of disease downstaging. Front. Endocrinol.(Lausanne) 9, 541 (2018).
  MedlineGoogle Scholar
• 46. Bustin SA, Benes V, Garson JA et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55(4), 611–622 (2009).
  Medline CASGoogle Scholar
• 47. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods 25(4), 402–408 (2001).
  Medline CASGoogle Scholar
• 48. Hebrant A, Dom G, Dewaele M et al. MRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch. PLoS ONE 7(10), e37807 (2012).
  Medline CASGoogle Scholar
• 49. Teng H, Mao F, Liang J et al. Transcriptomic signature associated with carcinogenesis and aggressiveness of papillary thyroid carcinoma. Theranostics 8(16), 4345–4358 (2018). • Explored a comprehensive transcriptomic signature associated with the carcinogenesis and aggressive behavior of papillary thyroid cancer that would facilitate the prognosis and development of new therapeutic strategies for this type of cancer.
  Medline CASGoogle Scholar
• 50. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. U S A 105(30), 10513–10518 (2008).
  Medline CASGoogle Scholar
• 51. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol. Med. 20(8), 460–469 (2014).
  Medline CASGoogle Scholar
• 52. Li S, Li J, Fei BY et al. MiR-27a promotes hepatocellular carcinoma cell proliferation through suppression of its target gene peroxisome proliferator-activated receptor gamma. Chin. Med. J. 128(7), 941–947 (2015).
  Medline CASGoogle Scholar
• 53. Tang KQ, Wang YN, Zan LS, Yang WC. MiR-27a controls triacylglycerol synthesis in bovine mammary epithelial cells by targeting peroxisome proliferator-activated receptor gamma. J. Dairy Sci. 100(5), 4102–4112 (2017).
  Medline CASGoogle Scholar
• 54. Kim SY, Kim AY, Lee HW et al. MiR-27a is a negative regulator of adipocyte differentiation via suppressing PPARgamma expression. Biochem. Biophys. Res. Commun. 392(3), 323–328 (2010).
  Medline CASGoogle Scholar
• 55. Liang J, Tang J, Shi H et al. MiR-27a-3p targeting RXRα promotes colorectal cancer progression by activating Wnt/β-catenin pathway. Oncotarget 8(47), 82991–83008 (2017).
  MedlineGoogle Scholar
• 56. Tombolan L, Zampini M, Casara S et al. MicroRNA-27a contributes to rhabdomyosarcoma cell proliferation by suppressing RARA and RXRA. PLoS ONE 10(4), e0125171 (2015).
  MedlineGoogle Scholar
• 57. Polvani S, Tarocchi M, Tempesti S, Bencini L, Galli A. Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer. World J. Gastroenterol. 22(8), 2441 (2016).
  Medline CASGoogle Scholar
• 58. Portius D, Sobolewski C, Foti M. MicroRNAs-dependent regulation of PPARs in metabolic diseases and cancers. PPAR Res. 2017, 7058424 (2017). • Uncovered the regulation of PPARs by miRNAs in the context of metabolic disorders, inflammation and cancer.
  MedlineGoogle Scholar
• 59. Oda Y, Nakajima M, Tsuneyama K et al. Retinoid X receptor α in human liver is regulated by miR-34a. Biochem. Pharmacol. 90(2), 179–187 (2014).
  Medline CASGoogle Scholar
• 60. Elnemr A, Ohta T, Iwata K et al. PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. Int. J. Oncol. 17(6), 1157–1221 (2000).
  Medline CASGoogle Scholar
• 61. Martelli ML, Iuliano R, Le Pera I et al. Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J. Clin. Endocrinol. Metab. 87(10), 4728–4735 (2002).
  Medline CASGoogle Scholar
• 62. Shen B, Chu ES, Zhao G et al. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice. Br. J. Cancer 106(9), 1486 (2012).
  Medline CASGoogle Scholar
• 63. Ogino S, Shima K, Baba Y et al. Colorectal cancer expression of peroxisome proliferator-activated receptor γ (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology 136(4), 1242–1250 (2009).
  Medline CASGoogle Scholar
• 64. Dobson ME, Diallo-Krou E, Grachtchouk V et al. Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma. Endocrinology 152(11), 4455–4465 (2011).
  Medline CASGoogle Scholar
• 65. Heaney AP, Fernando M, Melmed S. PPAR-γ receptor ligands: novel therapy for pituitary adenomas. J. Clin. Invest. 111(9), 1381–1388 (2003).
  Medline CASGoogle Scholar
• 66. Ishay-Ronen D, Diepenbruck M, Kalathur RKR et al. Gain fat—lose metastasis: converting invasive breast cancer cells into adipocytes inhibits cancer metastasis. Cancer Cell 35(1), 17–32.e6 (2019).
  Medline CASGoogle Scholar
• 67. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr. Biol. 11(10), 764–768 (2001).
  Medline CASGoogle Scholar
• 68. Vella V, Nicolosi ML, Giuliano S, Bellomo M, Belfiore A, Malaguarnera R. PPAR-γ agonists as antineoplastic agents in cancers with dysregulated IGF axis. Front. Endocrinol. (Lausanne) 8, 31 (2017).
  MedlineGoogle Scholar
• 69. Cui Y, Miyoshi K, Claudio E et al. Loss of the peroxisome proliferation-activated receptor gamma (PPARγ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J. Biol. Chem. 277(20), 17830–17835 (2002).
  Medline CASGoogle Scholar
• 70. Ikezoe T, Miller CW, Kawano S et al. Mutational analysis of the peroxisome proliferator-activated receptor γ gene in human malignancies. Cancer Res. 61(13), 5307–5310 (2001).
  Medline CASGoogle Scholar
• 71. Kosti I, Jain N, Aran D, Butte AJ, Sirota M. Cross-tissue analysis of gene and protein expression in normal and cancer tissues. Sci. Rep. 6(1), 1–6 (2016).
  MedlineGoogle Scholar